Navigation Links
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Date:11/19/2009

od of 2008 was primarily a result of the 2008 write-off of $1.9 million of deferred offering costs related to a delay in the Company's IPO. Also, in the 2009 period there were decreases in contract service costs associated with several of Omeros' clinical and preclinical programs and in clinical trial expenses due to the prior completion of enrollment in the Company's Phase 2 clinical study of OMS103HP for arthroscopic meniscectomy surgery.

Total operating expenses for the nine months ended September 30, 2009 were $16.5 million, compared to $19.1 million for the same period in 2008. The decrease in operating expenses in the nine months ended September 30, 2009 as compared to the same period of 2008 was primarily a result of items noted above.

Recent Highlights

  • Priced the Company's IPO on October 7, 2009, receiving net proceeds of approximately $61.8 million, and began trading on The NASDAQ Global Market under the ticker symbol "OMER" on October 8, 2009.
  • Announced positive results from the Phase 1/Phase 2 clinical trial of OMS302, Omeros' PharmacoSurgery product candidate being developed for use during ophthalmological procedures. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis), each with well-known safety and pharmacologic profiles. The Phase 1/Phase 2 trial enrolled 61 patients undergoing age-related cataract extraction with lens replacement, and was designed to evaluate efficacy and safety of OMS302 added to a standard surgical irrigation solution. Data from this study showed that patients treated with OMS302 reported less postoperative pain and demonstrated statistically significant improvement in maintenance of mydriasis during the surgical procedure compared to patients treated with vehicle control.
  • Amended its agreement with Patobios Limited by which Omeros has the exclusive right to acquire
    '/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 Dr. Sparano is Professor of ... at the Albert Einstein College of Medicine and Associate ... Medical Center. He is also Associate Director for ... the Einstein Breast Cancer Working Group, a multidisciplinary group ... research. He also serves as Vice Chair of the ...
(Date:5/17/2013)... This news release is available in German . ... all too well: with the naked eye, you can see ... bird in the blur of branches through the telephoto lens ... story for researchers who are looking to study proteins, the ... at ETH Zurich,s Institute for Molecular Systems Biology, and her ...
(Date:5/17/2013)... USA (PRWEB) May 17, 2013 •    First ... Globes Certified for sustainability ,     New facility will ... , Syngenta unveiled its new ... at the company’s RTP Innovation Center. The first of ... researchers to simulate any agricultural climate and precisely measure ...
(Date:5/17/2013)...  Yongye International, Inc. (NASDAQ: YONG ) ... distributor of crop nutrient products in the ... on May 16, 2013, the special committee (the "Special ... Directors") was provided a letter (the "Letter") issued by ... Limited ("Abax") to Full Alliance International Limited ("Full Alliance"). ...
Breaking Biology Technology:Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... against bacterial foes is to hide their food, particularly ... Vanderbilt University investigators has now discovered that a protein ... staph bacteria by sopping up manganese and zinc. , ... notion that binding metals to starve bacteria ...
... Jude Children,s Research Hospital(R), the premier pediatric research and ... ... Tenn., Feb. 14 More than 60,000 callers,generated $6.1 million ... by Univision Radio, a division of Univision,Communications Inc. The radiothon, ...
... Pipeline ... Continues to Mature, SOUTH SAN FRANCISCO, Calif., Feb. 14 ... full,year and fourth quarter ended December 31, 2007., Revenues for the ... revenues for the full year was primarily due to,revenue recognition associated with ...
Cached Biology Technology:Immune system protein starves 'staph' bacteria 2Immune system protein starves 'staph' bacteria 3More than $6 Million Raised During Two-Day Event to Support Research and Treatment for Childhood Cancer and Other Catastrophic Diseases 2More than $6 Million Raised During Two-Day Event to Support Research and Treatment for Childhood Cancer and Other Catastrophic Diseases 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9
(Date:5/16/2013)... at sites outside the bone marrow in the ... in Munich now show that a specific type of ... cells. , Balanced hematopoiesis is essential for the function ... place mainly in the liver and the spleen. Later ... this tissue normally serves as the sole source of ...
(Date:5/16/2013)... from Canada and around the world are meeting ... Neuroscience Meeting will showcase the latest in research ... reveal clues to understanding the disorders that affect ... and this meeting will showcase the best of ... says Sam David, President of the Canadian Association ...
(Date:5/16/2013)... ponder our pulses outside of the gym. But doctors use ... health. , Zhenan Bao, a professor of chemical engineering at ... bill and no wider than a postage stamp. The flexible ... is sensitive enough to help doctors detect stiff arteries and ... to continuously track heart health and provide doctors a safer ...
Breaking Biology News(10 mins):Herpes infections: Natural killer cells activate hematopoiesis 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3
... - The John Theurer Cancer Center at Hackensack University ... hospitals for cancer, will present research updates and clinical ... American Society of Hematology (ASH) Annual Meeting in San ... half of the John Theurer Cancer Center presentations showcased ...
... access to information about biodiversity is of crucial importance ... climate change research and education. "Non-Commercial" restrictions on the ... addressing these problems, says a review paper published in ... Halting the loss of biodiversity demands that information ...
... red blood cells provides protection against malaria caused by the ... Reserve University School of Medicine shows. The minute change, ... called the Duffy blood-group antigen, has been known for years. ... the parasite to lock onto the cell and gain entry. ...
Cached Biology News:National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting 2National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting 3National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting 4National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting 5National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting 6National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting 7Creative Commons 'non-commercial' licenses impede the re-use of biodiversity information 2Cell surface mutation protects against common type of malaria 2Cell surface mutation protects against common type of malaria 3
This device is designed to run four simultaneous separations with the following StemSep ; column sizes: 0.3in., 0.5in., and 0.6in.. Depending on the column size, a range of 2x10 7 - 1.5 x 10 9 cell...
Contact us for more information...
... 20-HETE is a cytochrome P450 (CYP450) metabolite ... the renal and cerebral vasculature. In rat ... mediates pressure-induced autoregulatory vasoconstriction. 20-HETE is excreted ... of free 20-HETE (20-40 pg/ml in human ...
Contact us for more information...
Biology Products: